Form D · Biotechnology

Mediar Therapeutics, Inc.

Boston, MA · CIK 0001766784

Offering snapshot reported Dec 23, 2025 · SEC filing

Reported sold
$37.8M
Offering amount: $75.7M
Investors reported
18
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 10, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 23, 2025Initial$37,849,815No comparison18SEC filing
Oct 22, 2024Amendment$85,034,866$24,432,246vs Nov 9, 202317SEC filing
Nov 9, 2023Amendment$60,602,620$28,841,434vs Dec 2, 202217SEC filing
Dec 2, 2022Initial$31,761,186No comparison17SEC filing
Feb 6, 2019Initial$5,000,000No comparison7SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-567903

Source: Form D, filed Dec 23, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Rahul Ballal Director, Executive
Michael Baran Director
Maina Bhaman Director
Cassidy Blundell Director
Stacey Brenner Executive
Adam Cotton Director
David De Graaf Director
Meredith Fisher Director
Brian Hubbard Director
Andreas Jurgeit Director
Anja Konig Director
Allan Marchington Director
Peter Parker Director
Marie Claire Peakman Director
Nandita Shangari Director
Bharat Srinivasa Director
Simon Sturge Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
20 Overland Street Suite 520
Boston, MA, 02215